Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
PAVmed reports former Exact Sciences CEO joins Lucid as vice chairman » 09:38
07/28/21
07/28
09:38
07/28/21
09:38
PAVM

PAVmed

$6.10 /

-0.14 (-2.25%)

, EXAS

Exact Sciences

$111.84 /

-1.61 (-1.42%)

PAVmed Inc. (PAVM)…

PAVmed Inc. (PAVM) announced that medical diagnostics pioneer Stanley N. Lapidus, founder and former Chairman and CEO of Exact Sciences (EXAS), has joined its majority owned subsidiary Lucid Diagnostics as Vice Chairman of Lucid's Board of Directors.

ShowHide Related Items >><<
PAVM PAVmed
$6.10 /

-0.14 (-2.25%)

EXAS Exact Sciences
$111.84 /

-1.61 (-1.42%)

PAVM PAVmed
$6.10 /

-0.14 (-2.25%)

03/29/21 Cantor Fitzgerald
PAVmed initiated with an Overweight at Cantor Fitzgerald
02/22/21 Lake Street
PAVmed price target raised to $9 from $5 at Lake Street
11/05/20
Fly Intel: Top five analyst initiations
11/05/20 Ascendiant
Ascendiant starts PAVmed with Buy on carpal tunnel potential
EXAS Exact Sciences
$111.84 /

-1.61 (-1.42%)

06/21/21 Wells Fargo
Exact Sciences price target raised to $120 from $115 at Wells Fargo
06/15/21 Raymond James
Exact Sciences initiated with a Strong Buy at Raymond James
06/15/21 Raymond James
Exact Sciences initiated with a Strong Buy at Raymond James
06/03/21 Goldman Sachs
Exact Sciences initiated with a Buy at Goldman Sachs
PAVM PAVmed
$6.10 /

-0.14 (-2.25%)

EXAS Exact Sciences
$111.84 /

-1.61 (-1.42%)

  • 23
    Feb
PAVM PAVmed
$6.10 /

-0.14 (-2.25%)

EXAS Exact Sciences
$111.84 /

-1.61 (-1.42%)

PAVM PAVmed
$6.10 /

-0.14 (-2.25%)

Over a week ago
Hot Stocks
PAVmed's Lucid Diagnostics launches partnership with UpScriptHealth » 09:32
07/22/21
07/22
09:32
07/22/21
09:32
PAVM

PAVmed

$5.83 /

+0.235 (+4.20%)

PAVmed announced that its…

PAVmed announced that its major subsidiary Lucid Diagnostics has entered into a definitive agreement with UpScriptHealth. Pursuant to the agreement, UpScript will support Lucid's upcoming EsoGuard Telemedicine Program by providing a Lucid-branded web-based telemedicine platform for patients with chronic heartburn symptoms to request video evaluation by a physician and, if clinically indicated, referral for Lucid's EsoGuard Esophageal DNA Test.

ShowHide Related Items >><<
PAVM PAVmed
$5.83 /

+0.235 (+4.20%)

PAVM PAVmed
$5.83 /

+0.235 (+4.20%)

03/29/21 Cantor Fitzgerald
PAVmed initiated with an Overweight at Cantor Fitzgerald
02/22/21 Lake Street
PAVmed price target raised to $9 from $5 at Lake Street
11/05/20
Fly Intel: Top five analyst initiations
11/05/20 Ascendiant
Ascendiant starts PAVmed with Buy on carpal tunnel potential
PAVM PAVmed
$5.83 /

+0.235 (+4.20%)

  • 23
    Feb
PAVM PAVmed
$5.83 /

+0.235 (+4.20%)

PAVM PAVmed
$5.83 /

+0.235 (+4.20%)

Over a month ago
Hot Stocks
Lucid Diagnostics completes CE Mark certification for EsoGuard Test » 09:32
06/10/21
06/10
09:32
06/10/21
09:32
PAVM

PAVmed

$5.80 /

-0.47 (-7.50%)

PAVmed announced that its…

PAVmed announced that its major subsidiary, Lucid Diagnostics, has completed European IVDD CE Mark certification of its EsoGuard Esophageal DNA Test. Lucid and its EU authorized representative completed the EC declaration of conformity procedure, including the associated technical documentation, ensuring and declaring that EsoGuard meets the essential requirements of Europe's In-Vitro Diagnostic Medical Devices Directive 98/79/EC. EsoGuard may now be marketed in CE Mark European countries, which include the European Economic Area, Switzerland, and, until July 1, 2023, the United Kingdom.

ShowHide Related Items >><<
PAVM PAVmed
$5.80 /

-0.47 (-7.50%)

PAVM PAVmed
$5.80 /

-0.47 (-7.50%)

03/29/21 Cantor Fitzgerald
PAVmed initiated with an Overweight at Cantor Fitzgerald
02/22/21 Lake Street
PAVmed price target raised to $9 from $5 at Lake Street
11/05/20
Fly Intel: Top five analyst initiations
11/05/20 Ascendiant
Ascendiant starts PAVmed with Buy on carpal tunnel potential
PAVM PAVmed
$5.80 /

-0.47 (-7.50%)

  • 23
    Feb
PAVM PAVmed
$5.80 /

-0.47 (-7.50%)

PAVM PAVmed
$5.80 /

-0.47 (-7.50%)

Hot Stocks
PAVmed launches digital health company Veris Health » 09:34
06/02/21
06/02
09:34
06/02/21
09:34
PAVM

PAVmed

$5.32 /

+0.02 (+0.38%)

PAVmed announced the…

PAVmed announced the launch of a new subsidiary, digital health company Veris Health, which acquired Oncodisc, a digital health company with tools to improve personalized cancer care through remote patient monitoring. Oncodisc was founded by experienced physician entrepreneurs, James Mitchell, M.D., who joins Veris as its full-time Chief Medical Officer, and Andrew Thoreson, M.D., who will serve as a Veris consultant. Oncodisc's core technologies include the first intelligent implantable vascular access port with biologic sensors and wireless communication, combined with an oncologist-designed remote digital healthcare platform that provides patients and physicians with new tools to improve outcomes and optimize the delivery of cost-effective care through remote monitoring and data analytics. Its groundbreaking vascular access port contains biologic sensors capable of generating continuous data on key physiologic parameters known to predict adverse outcomes in cancer patients undergoing treatment. Wireless communication to the patient's smartphone and its cloud-based digital healthcare platform efficiently and effectively delivers actionable real time data to patients and physicians. The technologies are the subject of multiple patent applications and one allowed patent awaiting final issuance. Veris is targeting FDA 510(k) clearance of the intelligent implantable vascular access port and launch of the remote digital healthcare platform for H2-2022. The planned Veris business model seeks to generate 100% recurring revenue through oncology practice and hospital-based subscriptions. These entities would purchase seats on the platform and pay a monthly remote monitoring charge to drive revenues from remote patient monitoring and device implantation under existing CPT codes, as well as established CMS Oncology Care Model bonuses and CMS Quality Reporting Program incentives. Veris also anticipates strong demand for its intelligent implantable vascular access port and remote monitoring platform from oncology biotherapeutic companies to support clinical trials of their novel immunotherapy and chemotherapy agents with continuous physiologic data and transformative analytics. PAVmed formed Veris Health Inc., a Delaware Corporation, as a wholly owned subsidiary, which in turn entered into a Stock Purchase Agreement to acquire 100% of the outstanding shares of Oncodisc Inc. from Oncodisc Holdings LLC, including all of Oncodisc's intellectual property, hardware, and software assets. In exchange, PAVmed granted Oncodisc Holdings LLC a 19.6% equity interest in Veris and provided $155,250 in cash to pay off two Oncodisc convertible notes. No additional cash consideration or PAVmed stock consideration was provided. A Shareholder Agreement between the parties provides additional terms and conditions concerning certain regulatory and commercial milestones, anti-dilution protection and other customary provisions. PAVmed will manage Veris through a Management Services Agreement until such time that the Veris Board of Directors decides to engage a dedicated management team and will finance its operations through intercompany advances until Veris decides to raise its own capital. Mitchell and Thoreson have entered into employment and consulting agreements, respectively, which include stringent intellectual property assignment and non-compete provisions.

ShowHide Related Items >><<
PAVM PAVmed
$5.32 /

+0.02 (+0.38%)

PAVM PAVmed
$5.32 /

+0.02 (+0.38%)

03/29/21 Cantor Fitzgerald
PAVmed initiated with an Overweight at Cantor Fitzgerald
02/22/21 Lake Street
PAVmed price target raised to $9 from $5 at Lake Street
11/05/20
Fly Intel: Top five analyst initiations
11/05/20 Ascendiant
Ascendiant starts PAVmed with Buy on carpal tunnel potential
PAVM PAVmed
$5.32 /

+0.02 (+0.38%)

  • 23
    Feb
PAVM PAVmed
$5.32 /

+0.02 (+0.38%)

PAVM PAVmed
$5.32 /

+0.02 (+0.38%)

Hot Stocks
PAVmed's Lucid Diagnostics receives CE Mark certification for EsoCheck device » 09:36
05/26/21
05/26
09:36
05/26/21
09:36
PAVM

PAVmed

$4.76 /

-0.005 (-0.11%)

PAVmed and its major…

PAVmed and its major subsidiary Lucid Diagnostics announced that Lucid's EsoCheck Esophageal Cell Collection Device with Collect+Protect technology has received CE Mark certification. EU-based Notified Body TundefinedV Rhineland LGA Products GMBH issued a CE Certificate, effective May 24, 2021, declaring that EsoCheck conforms to the essential requirements of Medical Device Directive 93/42/EEC. With CE Mark secured, EsoCheck may now be marketed in CE Mark European countries, which include the European Economic Area, Switzerland, and, until July 1, 2023, the United Kingdom.

ShowHide Related Items >><<
PAVM PAVmed
$4.76 /

-0.005 (-0.11%)

PAVM PAVmed
$4.76 /

-0.005 (-0.11%)

03/29/21 Cantor Fitzgerald
PAVmed initiated with an Overweight at Cantor Fitzgerald
02/22/21 Lake Street
PAVmed price target raised to $9 from $5 at Lake Street
11/05/20
Fly Intel: Top five analyst initiations
11/05/20 Ascendiant
Ascendiant starts PAVmed with Buy on carpal tunnel potential
PAVM PAVmed
$4.76 /

-0.005 (-0.11%)

  • 23
    Feb
PAVM PAVmed
$4.76 /

-0.005 (-0.11%)

PAVM PAVmed
$4.76 /

-0.005 (-0.11%)

Hot Stocks
PAVmed receives CE Mark for CarpX minimally invasive carpal tunnel device » 09:31
05/25/21
05/25
09:31
05/25/21
09:31
PAVM

PAVmed

$4.76 /

+0.17 (+3.70%)

PAVmed announced that it…

PAVmed announced that it has received CE Mark certification for its CarpX minimally invasive carpal tunnel device. EU-based Notified Body TundefinedV Rhineland LGA Products GMBH issued a CE Certificate, effective May 24, declaring that CarpX conforms to the essential requirements of Medical Device Directive 93/42/EEC. With CE Mark secured, CarpX may now be marketed in CE Mark European countries, which include the European Economic Area, Switzerland, and, until July 1, 2023, the United Kingdom.

ShowHide Related Items >><<
PAVM PAVmed
$4.76 /

+0.17 (+3.70%)

PAVM PAVmed
$4.76 /

+0.17 (+3.70%)

03/29/21 Cantor Fitzgerald
PAVmed initiated with an Overweight at Cantor Fitzgerald
02/22/21 Lake Street
PAVmed price target raised to $9 from $5 at Lake Street
11/05/20
Fly Intel: Top five analyst initiations
11/05/20 Ascendiant
Ascendiant starts PAVmed with Buy on carpal tunnel potential
PAVM PAVmed
$4.76 /

+0.17 (+3.70%)

  • 23
    Feb
PAVM PAVmed
$4.76 /

+0.17 (+3.70%)

PAVM PAVmed
$4.76 /

+0.17 (+3.70%)

Over a quarter ago
Options
Largest borrow rate increases among liquid names » 08:45
04/28/21
04/28
08:45
04/28/21
08:45
WRAP

Wrap Technologies

$6.24 /

-0.07 (-1.11%)

, GALT

Galectin Therapeutics

$4.16 /

-0.205 (-4.70%)

, WPRT

Westport

$7.30 /

+0.22 (+3.11%)

, SUNW

Sunworks

$12.25 /

-0.06 (-0.49%)

, DNN

Denison Mines

$1.03 /

-0.01 (-0.97%)

, REI

Ring Energy

$2.06 /

+0.06 (+3.00%)

, PAVM

PAVmed

$4.67 /

-0.15 (-3.12%)

, MAXN

Maxeon Solar

$20.01 /

-0.64 (-3.10%)

, OGI

Organigram

$2.62 /

-0.075 (-2.79%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: Silver Spike Acquisition Corp (SSPK) 12.96% +0.65, Wrap Technologies (WRAP) 14.98% +0.43, Galectin Therapeutics (GALT) 21.63% +0.37, Westport (WPRT) 4.57% +0.36, Sunworks (SUNW) 7.26% +0.32, Denison Mines (DNN) 2.58% +0.32, Ring Energy (REI) 2.62% +0.29, PAVmed (PAVM) 2.18% +0.24, Maxeon Solar Technologies (MAXN) 4.75% +0.21, and Organigram Holdings (OGI) 3.16% +0.17.

ShowHide Related Items >><<
WRAP Wrap Technologies
$6.24 /

-0.07 (-1.11%)

WPRT Westport
$7.30 /

+0.22 (+3.11%)

SUNW Sunworks
$12.25 /

-0.06 (-0.49%)

REI Ring Energy
$2.06 /

+0.06 (+3.00%)

PAVM PAVmed
$4.67 /

-0.15 (-3.12%)

OGI Organigram
$2.62 /

-0.075 (-2.79%)

MAXN Maxeon Solar
$20.01 /

-0.64 (-3.10%)

GALT Galectin Therapeutics
$4.16 /

-0.205 (-4.70%)

DNN Denison Mines
$1.03 /

-0.01 (-0.97%)

WRAP Wrap Technologies
$6.24 /

-0.07 (-1.11%)

04/15/21 Maxim
Wrap Technologies initiated with a Buy at Maxim
04/15/21 Maxim
Wrap Technologies initiated with a Buy at Maxim
GALT Galectin Therapeutics
$4.16 /

-0.205 (-4.70%)

04/16/21 H.C. Wainwright
Galectin Therapeutics price target raised to $14 from $12 at H.C. Wainwright
WPRT Westport
$7.30 /

+0.22 (+3.11%)

03/18/21 Lake Street
Lake Street confidence in Westport's China ramp boosted by Weichai deal
03/17/21 H.C. Wainwright
Westport price target raised to $16 from $5 at H.C. Wainwright
02/08/21 Craig-Hallum
Clean Energy price target raised to $25 from $12 at Craig-Hallum
02/08/21 Craig-Hallum
Westport target raised to $24 following Amazon truck order, says Craig-Hallum
SUNW Sunworks
$12.25 /

-0.06 (-0.49%)

04/26/21 Roth Capital
Sunworks resumed with a Neutral at Roth Capital
12/21/20 Roth Capital
ITC/PTC extensions likely included in COVID relief package, says Roth Capital
12/15/20 Roth Capital
Solar tax credit extension would be positive surprise, says Roth Capital
DNN Denison Mines
$1.03 /

-0.01 (-0.97%)

03/24/21 Raymond James
Denison Mines price target raised to C$1.70 from C$1.20 at Raymond James
02/25/21 TD Securities
Denison Mines price target raised to C$1.55 from C$1 at TD Securities
02/10/21 Raymond James
Denison Mines price target raised to C$1.20 from C$1.15 at Raymond James
01/21/21 Canaccord
Denison Mines price target raised to C$1.10 from C$0.90 at Canaccord
REI Ring Energy
$2.06 /

+0.06 (+3.00%)

03/08/21 Alliance Global Partners
Ring Energy assumed at Buy from Neutral at Alliance Global Partners
09/16/20 Alliance Global Partners
Ring Energy assumed with a Neutral at Alliance Global Partners
08/11/20 Alliance Global Partners
Ring Energy asset sale overhang remains, says Alliance Global Partners
PAVM PAVmed
$4.67 /

-0.15 (-3.12%)

03/29/21 Cantor Fitzgerald
PAVmed initiated with an Overweight at Cantor Fitzgerald
02/22/21 Lake Street
PAVmed price target raised to $9 from $5 at Lake Street
11/05/20
Fly Intel: Top five analyst initiations
11/05/20 Ascendiant
Ascendiant starts PAVmed with Buy on carpal tunnel potential
MAXN Maxeon Solar
$20.01 /

-0.64 (-3.10%)

04/12/21 Roth Capital
Maxeon Solar downgraded to Neutral from Buy at Roth Capital
04/12/21 Roth Capital
Maxeon Solar downgraded to Neutral from Buy at Roth Capital
02/08/21 Roth Capital
Bill could be 'meaningful positive' for solar stocks, says Roth Capital
01/19/21 Roth Capital
Maxeon Solar initiated with a Buy at Roth Capital
OGI Organigram
$2.62 /

-0.075 (-2.79%)

04/15/21 Stifel
Organigram price target raised to C$6 from C$4 at Stifel
04/14/21 Raymond James
Organigram price target lowered to C$5 from C$6 at Raymond James
04/14/21 Canaccord
Organigram price target raised to C$3.50 from C$2.00 at Canaccord
04/14/21 CIBC
CIBC downgrades Organigram to Underperformer with C$3.25 target
WPRT Westport
$7.30 /

+0.22 (+3.11%)

REI Ring Energy
$2.06 /

+0.06 (+3.00%)

PAVM PAVmed
$4.67 /

-0.15 (-3.12%)

OGI Organigram
$2.62 /

-0.075 (-2.79%)

MAXN Maxeon Solar
$20.01 /

-0.64 (-3.10%)

GALT Galectin Therapeutics
$4.16 /

-0.205 (-4.70%)

  • 16
    Apr
  • 23
    Feb
WPRT Westport
$7.30 /

+0.22 (+3.11%)

OGI Organigram
$2.62 /

-0.075 (-2.79%)

WPRT Westport
$7.30 /

+0.22 (+3.11%)

SUNW Sunworks
$12.25 /

-0.06 (-0.49%)

PAVM PAVmed
$4.67 /

-0.15 (-3.12%)

OGI Organigram
$2.62 /

-0.075 (-2.79%)

MAXN Maxeon Solar
$20.01 /

-0.64 (-3.10%)

GALT Galectin Therapeutics
$4.16 /

-0.205 (-4.70%)

WRAP Wrap Technologies
$6.24 /

-0.07 (-1.11%)

WPRT Westport
$7.30 /

+0.22 (+3.11%)

SUNW Sunworks
$12.25 /

-0.06 (-0.49%)

REI Ring Energy
$2.06 /

+0.06 (+3.00%)

PAVM PAVmed
$4.67 /

-0.15 (-3.12%)

OGI Organigram
$2.62 /

-0.075 (-2.79%)

MAXN Maxeon Solar
$20.01 /

-0.64 (-3.10%)

DNN Denison Mines
$1.03 /

-0.01 (-0.97%)

Options
In-the-money call buyers in PAVmed as shares bounce and volatility spikes » 10:10
04/07/21
04/07
10:10
04/07/21
10:10
PAVM

PAVmed

$6.53 /

+0.3 (+4.82%)

In-the-money call buyers…

In-the-money call buyers in PAVmed as shares bounce and volatility spikes. Shares of the medical device maker up a dime, or 1.6%, near $6.33 this morning after an early dip below $6, with 5600 calls trading in the first 20 minutes, vs 330 puts, and buyers focused on the April 5 calls, bought in a number of sweeps around 9:45am ET from 1.36 to 1.56 as shares lifted from $6.17 to $6.28. Implied volatility up nearly 40 points in the April term to 172%.

ShowHide Related Items >><<
PAVM PAVmed
$6.53 /

+0.3 (+4.82%)

PAVM PAVmed
$6.53 /

+0.3 (+4.82%)

03/29/21 Cantor Fitzgerald
PAVmed initiated with an Overweight at Cantor Fitzgerald
02/22/21 Lake Street
PAVmed price target raised to $9 from $5 at Lake Street
11/05/20
Fly Intel: Top five analyst initiations
11/05/20 Ascendiant
Ascendiant starts PAVmed with Buy on carpal tunnel potential
PAVM PAVmed
$6.53 /

+0.3 (+4.82%)

  • 23
    Feb
PAVM PAVmed
$6.53 /

+0.3 (+4.82%)

PAVM PAVmed
$6.53 /

+0.3 (+4.82%)

Initiation
PAVmed initiated with an Overweight at Cantor Fitzgerald » 16:47
03/29/21
03/29
16:47
03/29/21
16:47
PAVM

PAVmed

$3.92 /

-0.265 (-6.34%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Kyle Mikson initiated coverage of PAVmed with an Overweight rating and $8 price target. The analyst is citing the company's "unique" business model emphasizing capital efficiency and speed to market for its medical device products. Mikson adds that PAVmed's subsidiary Lucid Diagnostics could enable widespread BE-EAC screening, which he sees as a "large unmet need".

ShowHide Related Items >><<
PAVM PAVmed
$3.92 /

-0.265 (-6.34%)

PAVM PAVmed
$3.92 /

-0.265 (-6.34%)

02/22/21 Lake Street
PAVmed price target raised to $9 from $5 at Lake Street
11/05/20
Fly Intel: Top five analyst initiations
11/05/20 Ascendiant
Ascendiant starts PAVmed with Buy on carpal tunnel potential
11/05/20 Ascendiant
PAVmed initiated with a Buy at Ascendiant
PAVM PAVmed
$3.92 /

-0.265 (-6.34%)

  • 23
    Feb
PAVM PAVmed
$3.92 /

-0.265 (-6.34%)

PAVM PAVmed
$3.92 /

-0.265 (-6.34%)

Options
Three new option listings and two option delistings on February 25th » 08:30
02/25/21
02/25
08:30
02/25/21
08:30
PAVM

PAVmed

$4.67 /

+0.215 (+4.83%)

, HMI

Huami

$17.10 /

+0.42 (+2.52%)

, SNSS

Sunesis

$18.55 /

+3.64 (+24.41%)

New option listings for…

New option listings for February 25th include PAVmed (PAVM), Viracta Therapeutics Inc (VIRX), and Zepp Health Corporation (Class A ADS) (ZEPP). Option delistings effective February 25th include Huami Corporation (Class A ADS) (HMI) and Sunesis Pharmaceuticals Inc (SNSS).

ShowHide Related Items >><<
SNSS Sunesis
$18.55 /

+3.64 (+24.41%)

PAVM PAVmed
$4.67 /

+0.215 (+4.83%)

HMI Huami
$17.10 /

+0.42 (+2.52%)

PAVM PAVmed
$4.67 /

+0.215 (+4.83%)

02/22/21 Lake Street
PAVmed price target raised to $9 from $5 at Lake Street
11/05/20
Fly Intel: Top five analyst initiations
11/05/20 Ascendiant
Ascendiant starts PAVmed with Buy on carpal tunnel potential
11/05/20 Ascendiant
PAVmed initiated with a Buy at Ascendiant
HMI Huami
$17.10 /

+0.42 (+2.52%)

11/24/20 Credit Suisse
Huami downgraded to Neutral from Outperform at Credit Suisse
SNSS Sunesis
$18.55 /

+3.64 (+24.41%)

02/23/21 Oppenheimer
Sunesis upgraded to Outperform at Oppenheimer
02/23/21 Oppenheimer
Sunesis upgraded to Outperform from Perform at Oppenheimer
06/24/20 Oppenheimer
Sunesis downgraded to Perform at Oppenheimer
06/23/20 Oppenheimer
Sunesis downgraded to Perform from Outperform at Oppenheimer
SNSS Sunesis
$18.55 /

+3.64 (+24.41%)

PAVM PAVmed
$4.67 /

+0.215 (+4.83%)

HMI Huami
$17.10 /

+0.42 (+2.52%)

  • 23
    Feb
  • 29
    Jul
PAVM PAVmed
$4.67 /

+0.215 (+4.83%)

HMI Huami
$17.10 /

+0.42 (+2.52%)

SNSS Sunesis
$18.55 /

+3.64 (+24.41%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.